A landmark study by Hyderabad’s L V Prasad Eye Institute (LVPEI), published in the British Journal of Ophthalmology, has ...

This quick visual challenge will reveal whether you truly have the detail-oriented mind most people only wish they had.

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with ...

A highly specialized and multidisciplinary intervention was performed at the Sant'Anna and San Sebastiano Hospital in Caserta ...

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

FDA label expansion makes selumetinib the second MEK inhibitor approved for adults with neurofibromatosis type 1-associated ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

You know that tiny eye twitch that shows up right when your inbox explodes or after your third cup of coffee? We’ve all been ...

Best skincare products for rosacea, as approved by a rosacea sufferer and an expert. These products will reduce redness and ...

Investing.com -- OKYO Pharma Limited (NASDAQ:OKYO) stock rose 5.7% on Friday after the company announced that its Executive Chairman increased his ownership position in the company.

Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...

Also, at the outpatient department records of the National Radiotherapy Oncology and Nuclear Medicine Centre (NRONMC), KBTH, the total number of new head and neck cancer cases in 2024 was 292, 11.1% ...